Skip to main content

Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Publication ,  Journal Article
Islam, P; Rizzieri, D; Lin, C; de Castro, C; Diehl, L; Li, Z; Moore, J; Morris, T; Beaven, A
Published in: Cancer Invest
November 2021

Novel therapeutics are needed for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). Everolimus is an mTOR pathway inhibitor with synergistic anti-tumor activity when combined with histone deacetylase inhibitors, such as panobinostat, in preclinical lymphoma models. In this Phase II study, we evaluated overall response rate to single and combination everolimus and panobinostat in R/R DLBCL. Fifteen patients were enrolled to single-agent and 18 to combination. One patient responded to everolimus, while none responded to panobinostat. Though 25% of patients responded to combination therapy, responses were not durable with significant toxicity. We demonstrated minimal single-agent activity and prohibitive toxicity with combination therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer Invest

DOI

EISSN

1532-4192

Publication Date

November 2021

Volume

39

Issue

10

Start / End Page

871 / 879

Location

England

Related Subject Headings

  • Recurrence
  • Prospective Studies
  • Panobinostat
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Lymphoma, Large B-Cell, Diffuse
  • Humans
  • Female
  • Everolimus
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Islam, P., Rizzieri, D., Lin, C., de Castro, C., Diehl, L., Li, Z., … Beaven, A. (2021). Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Cancer Invest, 39(10), 871–879. https://doi.org/10.1080/07357907.2021.1983584
Islam, Prioty, David Rizzieri, Chenyu Lin, Carlos de Castro, Louis Diehl, Zhiguo Li, Joseph Moore, Tod Morris, and Anne Beaven. “Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Cancer Invest 39, no. 10 (November 2021): 871–79. https://doi.org/10.1080/07357907.2021.1983584.
Islam P, Rizzieri D, Lin C, de Castro C, Diehl L, Li Z, et al. Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Cancer Invest. 2021 Nov;39(10):871–9.
Islam, Prioty, et al. “Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Cancer Invest, vol. 39, no. 10, Nov. 2021, pp. 871–79. Pubmed, doi:10.1080/07357907.2021.1983584.
Islam P, Rizzieri D, Lin C, de Castro C, Diehl L, Li Z, Moore J, Morris T, Beaven A. Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Cancer Invest. 2021 Nov;39(10):871–879.

Published In

Cancer Invest

DOI

EISSN

1532-4192

Publication Date

November 2021

Volume

39

Issue

10

Start / End Page

871 / 879

Location

England

Related Subject Headings

  • Recurrence
  • Prospective Studies
  • Panobinostat
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Lymphoma, Large B-Cell, Diffuse
  • Humans
  • Female
  • Everolimus